Messina Sonia, Sframeli Maria, Maggi Lorenzo, D'Amico Adele, Bruno Claudio, Comi Giacomo, Mercuri Eugenio
Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
NEuroMuscular Omnicentre (NEMO) Sud Clinical Centre, University Hospital "G. Martino", Messina, Italy.
Neurol Sci. 2022 Dec;43(Suppl 2):615-624. doi: 10.1007/s10072-021-05258-3. Epub 2021 Apr 19.
Spinal muscular atrophy (SMA) is a severe disorder of motor neurons and the most frequent cause of genetic mortality, due to respiratory complications. We are facing an exciting era with three available therapeutic options in a disease considered incurable for more than a century. However, the availability of effective approaches has raised up ethical, medical, and financial issues that are routinely faced by the SMA community. Each therapeutic strategy has its weaknesses and strengths and clinicians need to know them to optimize clinical care. In this review, the state of the art and the results and challenges of the new SMA therapeutic strategies are highlighted.
脊髓性肌萎缩症(SMA)是一种严重的运动神经元疾病,也是因呼吸并发症导致遗传死亡的最常见原因。在一种被认为一个多世纪以来无法治愈的疾病中,我们正面临着一个令人兴奋的时代,有三种可用的治疗选择。然而,有效治疗方法的出现引发了SMA群体经常面临的伦理、医学和财务问题。每种治疗策略都有其优缺点,临床医生需要了解这些以优化临床护理。在这篇综述中,重点介绍了SMA新治疗策略的最新进展、结果和挑战。